BioAtla | Investor Presentation Deck

Slide schematic 5/5

disclaimer 1/1 list 3/3 title 1/1

Components 5

disclaimer bullet bullet bullet headline

Tools 1

2nd most common Soft Tissue Sarcoma (STS) subtype (~15% of all STS); High-grade aggressive subtype with high recurrence rates; 3k – 4k AXL+ addressable patients per year in the U.S.

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 0

∅

No frameworks

No framework match is anchored to this slide.

Find anything

The slide uses a structured list format to define the target market and unmet medical need.